Related Experiment Video
Updated: Jan 14, 2026
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Porphyrin-ligustrazine conjugates: Dual-mode therapeutic agents combining photodynamic and chemotherapy for enhanced
Lei Shi1, Yihui Liu2, Zeijie Tian1
1Institute of Pharmacy & Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang City, Hunan Province 421001, PR China.
Abstract:
Dual-mode therapeutic strategies have demonstrated substantially greater efficacy than single-modality treatments and hold broad clinical potential. In this study, we developed a series of 20 novel ligustrazine-porphyrin derivatives by integrating porphyrin-based photodynamic therapy (PDT) with ligustrazine chemotherapy. UV-vis spectroscopy confirmed that the characteristic photophysical features of porphyrins, including the Soret and Q bands, remained unchanged after conjugation with ligustrazine. Reactive oxygen species (ROS) detection assays revealed that all compounds were capable of generating ROS, with production further enhanced upon coordination with Zn(II). The derivatives exhibited varying levels of antitumor activity against HGC-27, A549, DU145, TCCSUP, HCT-116, and MDA-MB-231 cancer cell lines under both light and dark conditions, while demonstrating relatively lower cytotoxicity toward normal H9C2 cells. Among these compounds, derivative 8d showed the most pronounced antitumor activity.
Insights
Researchers created new ligustrazine-porphyrin compounds combining photodynamic therapy (PDT) and chemotherapy. Derivative 8d showed significant antitumor activity against multiple cancer cell lines with low toxicity to normal cells.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Oncology
Background:
- Dual-mode therapeutic strategies offer superior efficacy compared to single-modality treatments.
- Integrating photodynamic therapy (PDT) with chemotherapy presents a promising avenue for cancer treatment.
Purpose of the Study:
- To synthesize and characterize novel ligustrazine-porphyrin derivatives for dual-mode cancer therapy.
- To evaluate the photophysical properties, reactive oxygen species (ROS) generation, and antitumor activity of these derivatives.
Main Methods:
- Synthesis of 20 ligustrazine-porphyrin derivatives.
- UV-vis spectroscopy for photophysical characterization.
- ROS detection assays.
- In vitro evaluation of antitumor activity against various cancer cell lines (HGC-27, A549, DU145, TCCSUP, HCT-116, MDA-MB-231) and normal cells (H9C2).
Main Results:
- Porphyrin photophysical properties were maintained after conjugation with ligustrazine.
- All derivatives generated ROS, with enhanced production upon Zn(II) coordination.
- Compounds displayed varying antitumor activities under light and dark conditions.
- Derivative 8d exhibited the most potent antitumor effects with reduced cytotoxicity to normal cells.
Conclusions:
- Ligustrazine-porphyrin derivatives are effective dual-mode therapeutic agents.
- Derivative 8d demonstrates significant potential as a lead compound for cancer therapy.
- This dual-modality approach warrants further investigation for clinical applications.
More Related Videos
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...